As strong, antibody-mediated neutralizing activity increases with higher vaccine-induced anti-S1-antibody levels, comprehensively and longitudinally quantifying a potential difference in the humoral immunogenicity resulting from the approved mRNA vaccines in IRD patients and examining the effects of immunomodulatory treatments thereon may help to optimize COVID-19 vaccination strategies for this vulnerable patient population. The gene discussed is PSMD1; the disease is COVID-19.